Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE013 (USA) (Dr. Clarke)
· consented 2023-04-24
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-07-18 (study day 75); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 3 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2023-08-30 (study day 118); relationship: not assessed; serious criteria: hospitalization
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-02 (study day 151); relationship: N
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-12 (study day 253); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: UNKNOWN; onset 2024-01-28 (study day 269); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-06-03 (study day 396); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.